These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 11263719)

  • 21. Alzheimer and platelets: low-density platelet populations reveal increased serotonin content in Alzheimer type dementia.
    Milovanovic M; Eriksson K; Winblad B; Nilsson S; Lindahl TL; Post C; Järemo P
    Clin Biochem; 2014 Oct; 47(15):51-3. PubMed ID: 25041722
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serotoninergic antidepressants positively affect platelet ADAM10 expression in patients with Alzheimer's disease.
    Bianco OA; Manzine PR; Nascimento CM; Vale FA; Pavarini SC; Cominetti MR
    Int Psychogeriatr; 2016 Jun; 28(6):939-44. PubMed ID: 26555131
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in plasma and platelet BDNF levels induced by S-citalopram in major depression.
    Serra-Millàs M; López-Vílchez I; Navarro V; Galán AM; Escolar G; Penadés R; Catalán R; Fañanás L; Arias B; Gastó C
    Psychopharmacology (Berl); 2011 Jul; 216(1):1-8. PubMed ID: 21308467
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of fluvoxamine on platelet 5-HT2A receptors as studied by [3H]lysergic acid diethylamide ([3H]LSD) binding in healthy volunteers.
    Spigset O; Mjörndal T
    Psychopharmacology (Berl); 1997 Sep; 133(1):39-42. PubMed ID: 9335078
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia.
    Pollock BG; Mulsant BH; Rosen J; Mazumdar S; Blakesley RE; Houck PR; Huber KA
    Am J Geriatr Psychiatry; 2007 Nov; 15(11):942-52. PubMed ID: 17846102
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Binding of [3H]paroxetine to serotonin uptake sites and of [3H]lysergic acid diethylamide to 5-HT2A receptors in platelets from women with premenstrual dysphoric disorder during gonadotropin releasing hormone treatment.
    Bixo M; Allard P; Bäckström T; Mjörndal T; Nyberg S; Spigset O; Sundström-Poromaa I
    Psychoneuroendocrinology; 2001 Aug; 26(6):551-64. PubMed ID: 11403977
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial.
    Ehrhardt S; Porsteinsson AP; Munro CA; Rosenberg PB; Pollock BG; Devanand DP; Mintzer J; Rajji TK; Ismail Z; Schneider LS; Baksh SN; Drye LT; Avramopoulos D; Shade DM; Lyketsos CG;
    Alzheimers Dement; 2019 Nov; 15(11):1427-1436. PubMed ID: 31587995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Altered platelet serotonin 5-HT2A receptor density but not second messenger inositol trisphosphate levels in drug-free schizophrenic patients.
    Arranz B; Rosel P; Sarró S; Ramirez N; Dueñas R; Cano R; María Sanchez J; San L
    Psychiatry Res; 2003 May; 118(2):165-74. PubMed ID: 12798981
    [TBL] [Abstract][Full Text] [Related]  

  • 29. AT-1015, a novel serotonin (5-HT)2 receptor antagonist, blocks vascular and platelet 5-HT2A receptors and prevents the laurate-induced peripheral vascular lesion in rats.
    Kihara H; Hirose K; Koganei H; Sasaki N; Yamamoto H; Kimura A; Nishimori T; Shoji M; Yoshimoto R
    J Cardiovasc Pharmacol; 2000 Apr; 35(4):523-30. PubMed ID: 10774780
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Platelet serotonergic predictors of clinical improvement in obsessive compulsive disorder.
    Delorme R; Chabane N; Callebert J; Falissard B; Mouren-Siméoni MC; Rouillon F; Launay JM; Leboyer M
    J Clin Psychopharmacol; 2004 Feb; 24(1):18-23. PubMed ID: 14709942
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Platelet serotonergic indices in major depression: up-regulation of 5-HT2A receptors unchanged by antidepressant treatment.
    Hrdina PD; Bakish D; Ravindran A; Chudzik J; Cavazzoni P; Lapierre YD
    Psychiatry Res; 1997 Feb; 66(2-3):73-85. PubMed ID: 9075272
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship between central and peripheral serotonin 5-HT2A receptors: a positron emission tomography study in healthy individuals.
    Cho R; Kapur S; Du L; Hrdina P
    Neurosci Lett; 1999 Feb; 261(3):139-42. PubMed ID: 10081968
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Platelet serotonin-2A receptors: a potential biological marker for suicidal behavior.
    Pandey GN; Pandey SC; Dwivedi Y; Sharma RP; Janicak PG; Davis JM
    Am J Psychiatry; 1995 Jun; 152(6):850-5. PubMed ID: 7755113
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serotonergic Regulation and Cognition after Stroke: The Role of Antidepressant Treatment and Genetic Variation.
    Damsbo AG; Kraglund KL; Buttenschøn HN; Johnsen SP; Andersen G; Mortensen JK
    Cerebrovasc Dis; 2019; 47(1-2):72-79. PubMed ID: 30844812
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Upregulation of Cortical A2A Adenosine Receptors Is Reflected in Platelets of Patients with Alzheimer's Disease.
    Merighi S; Battistello E; Casetta I; Gragnaniello D; Poloni TE; Medici V; Cirrincione A; Varani K; Vincenzi F; Borea PA; Gessi S
    J Alzheimers Dis; 2021; 80(3):1105-1117. PubMed ID: 33646165
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of chronic ethanol consumption and aging on 5-HT2A receptors and 5-HT reuptake sites.
    Druse MJ; Tajuddin NF; Ricken JD
    Alcohol Clin Exp Res; 1997 Oct; 21(7):1157-64. PubMed ID: 9347073
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double-blind, placebo-controlled clinical trial.
    Mowla A; Mosavinasab M; Haghshenas H; Borhani Haghighi A
    J Clin Psychopharmacol; 2007 Oct; 27(5):484-7. PubMed ID: 17873681
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease.
    Small G; Erkinjuntti T; Kurz A; Lilienfeld S
    CNS Drugs; 2003; 17(12):905-14. PubMed ID: 12962529
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Citalopram plus low-dose pipamperone versus citalopram plus placebo in patients with major depressive disorder: an 8-week, double-blind, randomized study on magnitude and timing of clinical response.
    Wade AG; Crawford GM; Nemeroff CB; Schatzberg AF; Schlaepfer T; McConnachie A; Haazen L; Buntinx E
    Psychol Med; 2011 Oct; 41(10):2089-97. PubMed ID: 21349239
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of SSRI Therapy on Risk of Conversion From Mild Cognitive Impairment to Alzheimer's Dementia in Individuals With Previous Depression.
    Bartels C; Wagner M; Wolfsgruber S; Ehrenreich H; Schneider A;
    Am J Psychiatry; 2018 Mar; 175(3):232-241. PubMed ID: 29179578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.